novocure(NVCR) ZACKS·2025-02-20 16:06Core Viewpoint - The market anticipates NovoCure (NVCR) to report a year-over-year increase in earnings driven by higher revenues for the quarter ending December 2024, with actual results being crucial for stock price movement [1][2]. Financial Expectations - NovoCure is expected to report a quarterly loss of 161.3 million, indicating a 20.6% increase from the same quarter last year [3]. Estimate Revisions - The consensus EPS estimate has been revised 2.03% lower in the last 30 days, indicating a reassessment by analysts [4]. - The Most Accurate Estimate for NovoCure is lower than the Zacks Consensus Estimate, resulting in an Earnings ESP of -27.91% [10][11]. Earnings Surprise Prediction - The Zacks Earnings ESP model suggests that a positive or negative reading indicates the likely deviation of actual earnings from consensus estimates, with a strong predictive power for positive readings [6][7]. - Stocks with a positive Earnings ESP and a Zacks Rank of 1, 2, or 3 have historically produced positive surprises nearly 70% of the time [8]. Historical Performance - NovoCure has beaten consensus EPS estimates in the last four quarters, with a notable surprise of +17.65% in the last reported quarter [12][13]. Industry Comparison - Fate Therapeutics (FATE), another player in the biomedical sector, is expected to report an EPS of $0.44 for the same quarter, with a year-over-year change of +2.2% and revenues expected to decline by 24.4% [17]. - Fate Therapeutics has seen a 0.2% increase in its consensus EPS estimate over the last 30 days, but its Earnings ESP stands at 3.82% combined with a Zacks Rank of 4, making predictions of an earnings beat challenging [18].